Objective: Delayed neurodegeneration after transient global brain ischemia offers a therapeutic window for inhibiting molecular injury mechanisms. One such mechanism is calpain-mediated proteolysis, which peaks 24 to 48 hrs after transient forebrain ischemia in rats. This study tests the hypothesis that delayed calpain inhibitor therapy can reduce brain calpain activity and neurodegeneration after transient forebrain ischemia.
A key mechanism of neuronal death after transient global brain ischemia is disruption of Ca 2ϩ homeostasis (1) . An initial rise in cytosolic Ca 2ϩ during ischemia occurs in both selectively vulnerable and ischemia-resistant neurons (2) (3) (4) (5) . However, a delayed secondary increase in intracellular Ca 2ϩ occurs only in those neurons destined to die (6, 7) . One major effect of intracellular Ca 2ϩ overload is the activation of calpains, a family of Ca 2ϩdependent nonlysosomal neutral cysteine proteases. The proposed physiologic roles of calpains in the brain include regulation of neurite outgrowth (8) , long-term potentiation (9, 10) , and synaptic remod-eling (11) . More globally, calpains are involved in cell mitosis, migration, and differentiation (12) . Under physiologic conditions calpains are activated in response to transient localized increases in cytosolic Ca 2ϩ and regulated by calpastatin, an endogenous inhibitor protein. Under ischemic and postischemic conditions, intracellular Ca 2ϩ overload appears to overwhelm endogenous regulatory systems resulting in pathologic calpain activity.
A dramatic increase in calpain activity has been demonstrated during and after focal and global brain ischemia (13) (14) (15) (16) (17) (18) (19) (20) (21) . After transient forebrain ischemia (TFI) in rats, a bimodal pattern of calpainmediated alpha-spectrin degradation is observed in the hippocampus, with transient activity at 1 hr and peak activity occurring between 24 and 48 hrs after reperfusion (22) . The same study also found a progressive expansion of the number of neurons displaying calpain activity in the CA1 hippocampus between 24 and 48 hrs reperfusion. The calpain activity preceded both dendritic fragmentation and histologic evidence of neurodegeneration consistent with a causal relationship with neuronal death (22) .
The objective of this study was to evaluate the neuroprotective effect of calpain inhibitor therapy after TFI. Our unique approach was to match the timing of therapy with the time course of delayed postischemic calpain activity. Initiating therapy 22 hrs after reperfusion has the added benefit of exploiting a potentially broad therapeutic window for clinical translation. Our results suggest that this approach is effective, and support the hypothesis that calpains play a causal role in delayed postischemic neurodegeneration.
MATERIALS AND METHODS

Reagents
The water-soluble calpain inhibitor CEP-3453 was provided by Cephalon (West Chester, PA). CEP-3453 is the bisulfite addition product of the aldehyde of CEP-3122 [CH 3 SO 2 -D-(Bn)Ser-Phe-H] (23) . Rabbit polyclonal antibody directed at the calpain-derived fragment of alpha-spectrin (Ab38) was provided by Robert Siman (University of Pennsylvania, Philadelphia, PA). Mouse monoclonal antibody reacting with both intact and calpain-cleaved spectrin (MAB1622) was purchased from Chemicon International (Temecula, CA). Antirabbit fluorescent secondary antibody Alexa 568 was purchased from Molecular Probes (Eugene, OR). Hoechst 33258 was purchased from Sigma-Aldrich (St. Louis, MO). Reagents for enhanced chemiluminescence were purchased from Perkin-Elmer (Boston, MA).
Transient Global Forebrain Ischemia Model
Animal experiments were conducted in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals. The animal protocol was approved by our institution's Animal Care and Use Committee. Male Long-Evans rats weighing 400 to 500 g were anesthetized with halothane (3%), 70% N 2 O, and 30% O 2 by insufflation chamber and then maintained initially by facemask. Rats were orotracheally intubated with a 14 g angiocath and mechanically ventilated with a pressure-controlled small animal ventilator (initial settings; rate 80, peak inspiratory pressure 15 cm H 2 O, inspiration time 30%). A surgical plane of anesthesia was maintained with halothane (1.0%-1.5%) 70% N 2 O and 30% O 2 . PE-50 femoral arterial and venous catheters were placed by cut-down using aseptic technique. Temperature was monitored with a needle thermocouple probe inserted below the temporalis muscle. Temperature was maintained between 37.0°C and 38.0°C throughout the experimental period and up to 1 hr reperfusion by using a warming pad and overhead lamp. Electrocardiography was monitored by electrocardiographic limb leads. After a 10-min stabilization period, an arterial blood sample was obtained. Ventilator adjustments were made to maintain the PaCO 2 between 35 and 45 mm Hg.
TFI was initiated by the combination of bilateral carotid occlusion and hypovolemic hypotension to a mean arterial pressure of 30 to 35 mm Hg. Hypovolemic hypotension was achieved by rapidly withdrawing blood from the femoral arterial cannula and maintained during the ischemic period by withdrawal or infusion of blood through the femoral venous cannula. When a mean arterial pressure of 30 to 35 mm Hg was achieved, both carotid arteries were reversibly occluded with surgical aneurysm clips. The duration of ischemia was timed from when the aneurysm clips were placed. After 10 mins of ischemia, the aneurysm clips were removed and shed blood was reinfused through the femoral venous cannula. Rats were maintained on mechanical ventilation for 1 hr after which the arterial femoral cannula was removed. To enable continuous postanesthesia intravenous infusion, the proximal end of the femoral venous cannula was passed subcutaneously via trochar and externalized through a skin incision at the nape of the neck. The cannula was then pulled through a dacron mesh anchoring button that was sewn in place. The externalized portion of the cannula was covered with a protective tether attached to the anchoring button.
Rats were then extubated and administered oxygen through a face mask for an additional 30 mins. Rats were placed in a flat bottom recovery cage and the externalized femoral vein cannula was connected to an infusion swivel mounted above the cage. Intravenous infusion of 0.9% saline at 0.25 mL/kg/hr was initiated to keep the cannula patent until initiation of drug or vehicle therapy. Sham (uninjured) animals were subjected to anesthesia and surgical preparation without bilateral carotid occlusion and hypovolemic hypotension.
Experimental Protocols
Dose-Response Study. Twenty-two hours after TFI, rats were block randomized (n ϭ 3 per group) to either low-dose calpain inhibitor therapy (CEP-3453, 10 mg/kg intravenous [IV] bolus followed by 5 mg/kg/hr IV ϫ 26 hrs), mediumdose calpain inhibitor therapy (CEP-3453, 30 mg/kg IV bolus followed by 15 mg/kg/hr IV ϫ 26 hrs), high-dose calpain inhibitor therapy (CEP-3453, 60 mg/kg IV bolus followed by 30 mg/ kg/hr IV ϫ 26 hrs), or equal volume of drug vehicle (0.9% saline, 0.5 mL/kg IV bolus followed by 0.25 mL/kg/hr IV ϫ 26 hrs). Sham operated rats were used as controls. Rats surviving to 48 hrs were killed and hippocampal homogenates were generated for Western blot analysis of brain calpain activity.
Neuroprotection Study. Twenty-two hours after TFI, rats were block randomized (n ϭ 6 per group) to receive either high-dose calpain inhibitor (CEP-3453, 60 mg/kg IV bolus and 30 mg/kg IV infusion for 50 hrs) or vehicle (0.9% saline, 0.5 mL/kg IV bolus followed by 0.25 mL/kg/hr IV ϫ 50 hrs). Sham operated rats served as controls (n ϭ 6). Rats were killed 72 hrs after injury and brains were processed for immunohistochemistry and fluorescence Microscopy.
Western Blot Tests. After decapitation under general anesthesia brains were rapidly microdissected on an ice-chilled plate. The dorsal hippocampus was homogenized using a 2.0 mL Wheaton dounce homogenizer and a type B pestle in 10:1 vol/wt buffer containing 10 mM Tris (pH 7.4), 10 mM EGTA, 250 mM sucrose, 2 g/mL aprotinin, 5 g/mL leupeptin, 2 g/mL pepstatin, and 1 mM PMSF. Protein concentration was determined by the Bradford assay method. Samples (100 g) were mixed 1:1 in 2X loading buffer and separated by sodium dodecyl sulfate polyacrylamide gel (7.5% T, 2.5% C) followed by electroblot transfer to nitrocellulose. The nitrocellulose membrane was rinsed in Tween-Tris-buffered saline (20 mM Tris base [pH 7.6], 137 mM NaCl, 0.1% Tween 20) and then preblocked for one hour at room temperature in Tween-Tris-buffered saline containing 5% powdered milk. Membranes were then probed with anti-alpha-spectrin primary monoclonal mouse antibody (MAB 1622, Chemicon; 1:5,000) in Tween-Tris-buffered saline for 1 hour at room temperature. This antibody reacts with both intact alpha-spectrin and the 145/150 kDa doublet produced by calpainmediated cleavage. Secondary antibody was HRP-linked anti-mouse IgG (1:10:000, Perkin-Elmer) in Tween-Tris-buffered saline for 30 mins at room temperature. Blots were developed by enhanced chemiluminescence (Perkin-Elmer). Band densities were quantified by computer densitometry and analyzed. One-way analysis of variance with Scheffe posthoc analysis was used to compare ischemia-induced change in mean 145/150 kDa densities relative to vehicle-treated controls for each drug dose and brain region. Results are expressed as mean Ϯ SD.
Immunohistochemistry and Epifluorescence Microscopy. Rats were killed by perfusion fixation with 4% paraformaldehyde under general anesthesia. After perfusion fixation, brains were removed and postfixed overnight in 4% paraformaldehyde followed by serial incubations in 10%, 20%, and 30% sucrose until brains sank to the bottom of the vial. Brains were then frozen in dry ice ethanol slurry and 40 m sections generated using a freezing sliding microtome.
Brain sections were washed in 20 mM Tris and 150 mM NaCl (Tris-buffered saline), pH 7.4, and preblocked in 5% normal goat serum containing 0.1% Triton X-100 in Tris-buffered saline (Block). Sections were then incubated overnight at 4°C with primary rabbit polyclonal antibody (Ab38, 1:20,000) diluted in blocking solution. Ab38 specifically detects calpain-cleaved alpha-spectrin (17) . Sections were washed in Tris-buffered saline, and then incubated with anti-rabbit fluorescent secondary antibody Alexa 568 (Molecular Probes) for 60 min at room temperature. All sections were counterstained with Hoechst 33258 (2.5 g/mL in Tris-buffered saline, Sigma). The slides were mounted with Fluoromount medium (Beckman Coulter, Fullerton, CA). Negative controls were prepared identically except for omission of the primary antibody. To evaluate the effect of calpain inhibition on caspase activity, a subset of sections were immunolabeled with primary antibody Ab246 which specifically detects the caspase-derived fragment of alpha-spectrin (24) .
Calpain activity was quantified by regional Ab38 immunofluorescence in the CA1 sector hippocampus at Ϫ2.6 and Ϫ3.6 relative to bregma. Epifluorescence images were captured at 100ϫ magnification using Nikon Eclipse E600 epifluorescence microscope with a rhodamine filter (510 -560/590 nm), a digital 12 megapixel camera (Nikon Instruments, Melville, NY), and a Dell PowerEdge 1300 computer (Round Rock, TX). Intensity settings were initially adjusted to minimize background fluorescence and then all images were captured at the same settings. Regional CA1 fluorescence was quantified by computerized densitometry (ImageQuant densitometric software, Molecular Dynamics, Sunnyvale, CA), and the average of the two regions examined in each animal was calculated. Mean Ab38 fluorescence intensity in the vehicle and CEP-3453 treatment groups was statistically compared using a twotailed Student's t-test (alpha error 0.05). Results are expressed as mean Ϯ SD.
Neurodegeneration was quantified by counting normal appearing Hoechst-stained neuronal nuclei in the hippocampal CA1 pyramidal layer at Ϫ2.6 and Ϫ3.6 relative to bregma. Epifluorescence images using a DAPI filter set were obtained at 200ϫ magnification in the focal plane with the greatest number of nuclei. Any nuclei that were out of focus were not counted regardless of morphology. Normal-appearing nuclei, defined as rounded with dispersed granular chromatin, were counted by five investigators blinded to treatment and mean values were used for analysis. The normal nuclei counts were compared between vehicle and CEP-3453 treatment groups using a two-tailed Student's t-test (alpha error 0.05). Results are expressed as mean Ϯ SD.
RESULTS
Dose Efficacy of Delayed CEP-3453
Treatment. Western blot analysis of hippocampal homogenates from vehicletreated rats 48 hrs after TFI revealed signif-icant calpain activity as demonstrated by the characteristic 145/150 kDa doublet produced by calpain-mediated cleavage of alpha-spectrin ( Fig. 1A) . Calpain activity was negligible in sham operated controls using this assay. Delayed CEP-3453 calpain inhibitor therapy at low and medium doses did not diminish ischemia-induced calpain activity. In contrast, delayed administration of CEP-3453 at the highest dose tested (900 mg/kg total dose) had a dramatic effect on postischemic calpain activity. At this dose, the ischemia-induced increase in the mean 145/ 150 kDa doublet density was reduced by 97% Ϯ 3% (p Ͻ .05, Fig. 1B) .
Postischemic Neuroprotection. Relative to sham-operated controls, mean CA1 sector Ab38 immunofluorescence in-creased by 263% Ϯ 281% in vehicletreated rats and 68% Ϯ 147% in CEP-3453 treated rats (p ϭ .17) (Fig. 2) . Although not statistically significant, this result is consistent with our Western blot data demonstrating CEP-3543-mediated inhibition of delayed postischemic calpain activity in hippocampus. As illustrated in Figure 2 , calpain-mediated spectrin cleavage is detectable throughout the stratum oriens, stratum pyramidale, stratum radiatum and most prominent in the stratum lacunosum moleculare. There was no detectable increased in Ab246 labeling in the CA1 sector of vehicle or CEP-3453 treated groups relative to sham-injured rats (data not shown). Therefore, we found no evidence that calpain inhibition caused a secondary upregulated caspase activity in this model. Normal CA1 pyramidal layer nuclei averaged 10% Ϯ 12% of control in vehicle-treated TFI rats and 50% Ϯ 42% of control in CEP-3453 treated TFI rats (p ϭ .047) ( Fig. 3 ).
DISCUSSION
In this study, IV administration of the calpain inhibitor CEP-3453 beginning 22 hrs after TFI effectively inhibited calpainmediated alpha-spectrin degradation in the postischemic hippocampus. Doseresponse analysis revealed that effectiveness was dependent on a relatively high dose of drug administration (CEP-3453 60 mg/kg IV bolus and 30 mg/kg IV continuous infusion). Analysis of neurodegeneration 72 hrs after injury reveals evidence of neuroprotection with high-dose therapy in the CA1 sector pyramidal neurons of the hippocampus. This study is significant in that it demonstrates: 1) that intravenously administered CEP-3453 effectively inhibits brain calpain activity, 2) the effectiveness of matching calpain inhibitor therapy with the time course of postischemic calpain activity, and 3) the broad therapeutic window for calpain inhibition after transient global brain ischemia.
Previous studies have demonstrated neuroprotective effects of postischemic calpain inhibitor therapy (15, (25) (26) (27) (28) (29) (30) (31) . However, the effectiveness of calpain inhibition in these studies was incomplete and may have been limited by the fact that drug administration was not synchronized to the time course of calpain activity in the postischemic brain. After TFI in rats, a bimodal pattern calpain activity is observed, with an initial minor peak occurring at 1 hr after reperfusion and a major (10-fold greater) secondary peak occurring between 24 and 48 hrs after reperfusion (22) . No previous studies have examined either delayed or sustained calpain inhibitor therapy directed at attenuating the secondary peak in calpain activity after transient global brain ischemia.
This study focuses on the role of calpains in delayed postischemic neurodegeneration. However, direct and indirect effects of CEP-3453 on other pathologic proteases cannot be completely ruled out. CEP-3453 is the bisulfite addition product of the aldehyde of CEP-3122 [CH 3 SO 2 -D-(Bn)Ser-Phe-H] (23). Both compounds have an IC 50 of 8.0 nM for -calpain in vitro and 0.7 M for calpain activity in intact cell culture (23) (Ming Tao, unpublished data) which is similar to the commonly used calpain inhibitor MDL-28170 (32) . Similar to other calpain inhibitors in this class, CEP-3453 has inhibitory activity against cathepsin B (IC 50 15 nM). The role of cathepsin B in postischemic neurodegeneration remains controversial, but there is evidence that lysosomal cathepsins are released secondary to calpain-mediated cleavage of lysosomal membrane proteins (33) . Therefore, direct or indirect inhibition of cathepsin activity cannot be ruled out in this study. Although CEP-3453 has no direct effect on caspases, calpain inhibition can indirectly affect caspase activity through multiple mechanisms of cross-talk (34) . However, in the CA1 pyramidal neuron population that was the focus of this study, we are unable to detect significant caspase-mediated cleavage of alpha-spectrin without or with CEP-3453 treatment.
A number of potential mechanisms have been identified to explain the neuroprotective effect of delayed calpain inhibition. Transient calcium fluxes induced by ischemia and initial reperfusion occur in most brain cells (2) (3) (4) (5) . However, a well-documented phenomenon of delayed secondary calcium overload is closely associated with delayed postischemic neurodegeneration (6, 7) . The mechanism of delayed secondary neuronal calcium overload remains controversial. The majority of calcium regulatory proteins in the synapse, plasma membrane, and endoplasmic reticulum are known calpain substrates. Furthermore, calpain cleavage of these proteins causes dysregulation of function that in most cases could contribute to sustained elevations in cytosolic calcium. Therefore, the potential net effect of pathologic calpain activity once triggered is a feedforward mechanism of cytosolic calcium overload and sustained calpain activity leading to neuronal death. In addition to disruption of the calcium regulatory system, a number of other molecules associated with cell survival/ death signaling have been linked to calpain-mediated cell death including BCL family proteins (35) (36) (37) , caspases (38, 39) AIF (40) , CRMP3 (41), p25/CKD5 (42, 43) , and p53 (44, 45) . Furthermore calpain-mediated degradation of lysosomal membrane proteins and subsequent cathepsin release has been proposed as a mechanism of postischemic neurodegeneration (46) . The relative role of various calpain substrates in postischemic neurodegeneration is an area of ongoing investigation.
In addition to the potential mechanisms of neuroprotection, several key questions must be addressed regarding the therapeutic paradigm in our study. Most importantly, it remains to be determined if delayed calpain inhibitor therapy results in sustained neuroprotection (beyond 72 hrs) and preserved neuronal function. Future studies will need to examine more long-term and functional outcomes. Furthermore, the relative contribution of early and late postischemic calpain activity to delayed neuronal death needs to be explored further. Perhaps optimal therapy will require inhibition of both. Finally, because the cause of delayed postischemic calpain activation remains to be elucidated, the optimal duration of calpain inhibitor will need to be examined.
We have demonstrated for the first time that initiating therapy 22 hrs after transient global brain ischemia significantly impacts an important biochemical injury pathway. This novel observation has obvious clinical implications. Although the phenomenon of delayed postischemic neuronal death is well accepted, the effectiveness of delayed therapy has not been explored due to the assumption that injury pathways are maximally active during ischemia and early reperfusion. If future studies demonstrate that delayed calpain inhibitor therapy results in sustained functional neuroprotection, the overall approach to brain resuscitation after global ischemic insults such as cardiac arrest will need to be revised. 
